1,25(OH) 2 D 3 alleviates DSS-induced ulcerative colitis via inhibiting NLRP3 inflammasome activation.
Level 5 - mechanism / opinion, no new human data
Bench and animal model (in vitro and DSS mouse model) with no human clinical data
PubMed 32237257 · doi:10.1002/JLB.3MA0320-406RR
What was done
Investigators evaluated the anti-inflammatory mechanism of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3, VitD3) on NOD-like receptor protein 3 (NLRP3) inflammasome activation in cellular assays and in a dextran sulfate sodium (DSS)-induced mouse model of ulcerative colitis. They assessed downstream markers including caspase-1 activation, interleukin-1β (IL-1β) secretion, ASC oligomerization, NEK7-NLRP3 binding, autophagy, and uncoupling protein 2-reactive oxygen species (UCP2-ROS) signaling.
What was found
The abstract reports no quantitative values or effect sizes. VitD3 abolished NLRP3 inflammasome activation, inhibited caspase-1 activation, and suppressed IL-1β secretion through the vitamin D receptor (VDR). VitD3 also blocked ASC oligomerization, prevented NLRP3 binding to NEK7, and inhibited autophagy. In the animal model, VitD3 showed both preventive and therapeutic effects against DSS-induced colitis via NLRP3 suppression.
Why it matters
The study outlines a direct molecular pathway through which active vitamin D suppresses the NLRP3 inflammasome, offering a mechanistic rationale for testing vitamin D-based therapies in autoimmune and inflammasome-driven inflammatory disorders.
Limits
The abstract provides no quantitative data, sample sizes, or dosing regimens. Findings are limited to in vitro experiments and a chemically induced mouse model (DSS), which does not fully capture human ulcerative colitis. Clinical efficacy and safety in humans were not evaluated.
Cited by
- supports Activation of the vitamin D receptor downregulates the NLRP3 inflammasome.